PKM2, a Central Point of Regulation in Cancer Metabolism

Overview

Journal Int J Cell Biol

Publisher Wiley

Specialty Cell Biology

Date 2013 Mar 12

PMID 23476652

Citations 114

Authors

Nicholas Wong

Jason De Melo

Damu Tang

Affiliations

Soon will be listed here.

Abstract

Aerobic glycolysis is the dominant metabolic pathway utilized by cancer cells, owing to its ability to divert glucose metabolites from ATP production towards the synthesis of cellular building blocks (nucleotides, amino acids, and lipids) to meet the demands of proliferation. The M2 isoform of pyruvate kinase (PKM2) catalyzes the final and also a rate-limiting reaction in the glycolytic pathway. In the PK family, PKM2 is subjected to a complex regulation by both oncogenes and tumour suppressors, which allows for a fine-tone regulation of PKM2 activity. The less active form of PKM2 drives glucose through the route of aerobic glycolysis, while active PKM2 directs glucose towards oxidative metabolism. Additionally, PKM2 possesses protein tyrosine kinase activity and plays a role in modulating gene expression and thereby contributing to tumorigenesis. We will discuss our current understanding of PKM2's regulation and its many contributions to tumorigenesis.

Citing Articles

The Role of the Dysregulation of circRNAs Expression in Glioblastoma Multiforme.

Wang Y, Yu Y, Yu J, Wang C, Wang Y, Fu R J Mol Neurosci. 2025; 75(1):9.

PMID: 39841303 DOI: 10.1007/s12031-024-02285-5.

SRT3025-loaded cell membrane hybrid liposomes (3025@ML) enhanced anti-tumor activity of Oxaliplatin via inhibiting pyruvate kinase M2 and fatty acid synthase.

Wang X, Li S, Li Z, Lin Z, Wang Z Lipids Health Dis. 2025; 24(1):14.

PMID: 39825408 PMC: 11740399. DOI: 10.1186/s12944-025-02431-x.

Effective-Component Compatibility of Bufei Yishen Formula III Suppresses Mitochondrial Oxidative Damage in COPD: Via Pkm2/Nrf2 Pathway.

Liu Y, Zhang L, Zhao J, Lu R, Shao X, Xu K Int J Chron Obstruct Pulmon Dis. 2024; 19:1905-1920.

PMID: 39206144 PMC: 11352541. DOI: 10.2147/COPD.S468825.

Chrysophanol inhibits of colorectal cancer cell motility and energy metabolism by targeting the KITENIN/ErbB4 oncogenic complex.

Varli M, Kim E, Oh S, Pulat S, Zhou R, Gamage C Cancer Cell Int. 2024; 24(1):253.

PMID: 39030594 PMC: 11264950. DOI: 10.1186/s12935-024-03434-x.

The role of PKM2 in cancer progression and its structural and biological basis.

Wu B, Liang Z, Lan H, Teng X, Wang C J Physiol Biochem. 2024; 80(2):261-275.

PMID: 38329688 DOI: 10.1007/s13105-024-01007-0.

References

Hitosugi T, Kang S, Vander Heiden M, Chung T, Elf S, Lythgoe K . Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth. Sci Signal. 2009; 2(97):ra73. PMC: 2812789. DOI: 10.1126/scisignal.2000431. View

Wang S, Bourguignon L . Role of hyaluronan-mediated CD44 signaling in head and neck squamous cell carcinoma progression and chemoresistance. Am J Pathol. 2011; 178(3):956-63. PMC: 3069910. DOI: 10.1016/j.ajpath.2010.11.077. View

Ye J, Mancuso A, Tong X, Ward P, Fan J, Rabinowitz J . Pyruvate kinase M2 promotes de novo serine synthesis to sustain mTORC1 activity and cell proliferation. Proc Natl Acad Sci U S A. 2012; 109(18):6904-9. PMC: 3345000. DOI: 10.1073/pnas.1204176109. View

Wechsel H, Petri E, Bichler K, Feil G . Marker for renal cell carcinoma (RCC): the dimeric form of pyruvate kinase type M2 (Tu M2-PK). Anticancer Res. 1999; 19(4A):2583-90. View

Kwon O, Kang T, Kim J, Kim M, Noh S, Song K . Pyruvate kinase M2 promotes the growth of gastric cancer cells via regulation of Bcl-xL expression at transcriptional level. Biochem Biophys Res Commun. 2012; 423(1):38-44. DOI: 10.1016/j.bbrc.2012.05.063. View

Warburg O, Wind F, Negelein E . THE METABOLISM OF TUMORS IN THE BODY. J Gen Physiol. 2009; 8(6):519-30. PMC: 2140820. DOI: 10.1085/jgp.8.6.519. View

Vander Heiden M, Christofk H, Schuman E, Subtelny A, Sharfi H, Harlow E . Identification of small molecule inhibitors of pyruvate kinase M2. Biochem Pharmacol. 2009; 79(8):1118-24. PMC: 2823991. DOI: 10.1016/j.bcp.2009.12.003. View

Kefas B, Comeau L, Erdle N, Montgomery E, Amos S, Purow B . Pyruvate kinase M2 is a target of the tumor-suppressive microRNA-326 and regulates the survival of glioma cells. Neuro Oncol. 2010; 12(11):1102-12. PMC: 3098027. DOI: 10.1093/neuonc/noq080. View

Pfeiffer T, Schuster S, Bonhoeffer S . Cooperation and competition in the evolution of ATP-producing pathways. Science. 2001; 292(5516):504-7. DOI: 10.1126/science.1058079. View

10.

Wenger R, Gassmann M . Oxygen(es) and the hypoxia-inducible factor-1. Biol Chem. 1997; 378(7):609-16. View

11.

Hsu P, Sabatini D . Cancer cell metabolism: Warburg and beyond. Cell. 2008; 134(5):703-7. DOI: 10.1016/j.cell.2008.08.021. View

12.

Clower C, Chatterjee D, Wang Z, Cantley L, Vander Heiden M, Krainer A . The alternative splicing repressors hnRNP A1/A2 and PTB influence pyruvate kinase isoform expression and cell metabolism. Proc Natl Acad Sci U S A. 2010; 107(5):1894-9. PMC: 2838216. DOI: 10.1073/pnas.0914845107. View

13.

Luo W, Semenza G . Pyruvate kinase M2 regulates glucose metabolism by functioning as a coactivator for hypoxia-inducible factor 1 in cancer cells. Oncotarget. 2011; 2(7):551-6. PMC: 3248177. DOI: 10.18632/oncotarget.299. View

14.

Jahns F, Wilhelm A, Greulich K, Mothes H, Radeva M, Wolfert A . Impact of butyrate on PKM2 and HSP90β expression in human colon tissues of different transformation stages: a comparison of gene and protein data. Genes Nutr. 2011; 7(2):235-46. PMC: 3316742. DOI: 10.1007/s12263-011-0254-6. View

15.

Hoshino A, Hirst J, Fujii H . Regulation of cell proliferation by interleukin-3-induced nuclear translocation of pyruvate kinase. J Biol Chem. 2007; 282(24):17706-11. DOI: 10.1074/jbc.M700094200. View

16.

Wang G, Jiang B, Rue E, Semenza G . Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci U S A. 1995; 92(12):5510-4. PMC: 41725. DOI: 10.1073/pnas.92.12.5510. View

17.

Zhou C, Li X, Sun H, Zhang B, Han Y, Jiang Y . Pyruvate kinase type M2 is upregulated in colorectal cancer and promotes proliferation and migration of colon cancer cells. IUBMB Life. 2012; 64(9):775-82. DOI: 10.1002/iub.1066. View

18.

Wang C, Delogu S, Ho C, Lee S, Gui B, Jiang L . Inactivation of Spry2 accelerates AKT-driven hepatocarcinogenesis via activation of MAPK and PKM2 pathways. J Hepatol. 2012; 57(3):577-83. PMC: 3423481. DOI: 10.1016/j.jhep.2012.04.026. View

19.

Lim J, Yoon S, Seol S, Hong S, Kim J, Choi S . Overexpression of the M2 isoform of pyruvate kinase is an adverse prognostic factor for signet ring cell gastric cancer. World J Gastroenterol. 2012; 18(30):4037-43. PMC: 3420001. DOI: 10.3748/wjg.v18.i30.4037. View

20.

Bluemlein K, Gruning N, Feichtinger R, Lehrach H, Kofler B, Ralser M . No evidence for a shift in pyruvate kinase PKM1 to PKM2 expression during tumorigenesis. Oncotarget. 2011; 2(5):393-400. PMC: 3248187. DOI: 10.18632/oncotarget.278. View